Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide for Children With Autism Spectrum Disorder
NCT03156153Phase 2Completed
- Sponsor
- Xinhua Hospital
- Start
- May 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bumetanide in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Childhood Autism Rating Scale at Day 90. Started May 2017; status: completed.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03156153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156153.